Depression following psychosis is common and can impact negatively on individuals' quality of life. This study conducted post-hoc analyses on 14 participants with psychosis from a larger randomised controlled trial who presented with clinically important levels of depression at baseline. Eight of the participants received Acceptance and Commitment Therapy (ACT), whilst the remaining six individuals received treatment as usual (TAU). The focus was on investigating clinically significant change in outcome measures between baseline and 3-months post-baseline in the participants. Participants completed measures assessing depression and anxiety (HADS), psychosis symptoms (PANSS) and psychological inflexibility (AAQ-II) between baseline and at 3-month post-baseline assessments. Odds ratio analysis indicated that participants receiving ACT, compared to TAU, were 15 times more likely to achieve clinically significant decreases in depression scores (Fisher's Exact Test p = 0.05). Differences between the ACT and TAU groups in clinically significant changes in anxiety, psychological inflexibility, positive symptoms, negative symptoms and general level of psychopathology were not statistically significant. The study provides tentative support for the use of ACT to treat depression emerging in the context of psychosis.
Acceptance and Commitment Therapy for
Depression following psychosis: An examination of clinically significant change White 
Introduction
The experience of psychosis is associated with increased levels of depression . Those who develop depression appraise psychosis as a humiliating threat to their future status that will lead to the loss of a sense of personally valued social roles and goals (Birchwood et al., 2006; Birchwood et al., 2000) . Consistent with these threat appraisals, internalised stigma and shame are key features evident in depression occurring in the context of schizophrenia (Gumley et al., 2010) . Prevalence studies show that several months after an acute episode of psychosis, rates of depression can be up to 50% of cases (Whitehead et al., 2002; Birchwood, 2003) . Depression has been identified as a major factor contributing to poor quality of life in individuals with psychosis (Saarni et al., 2010; Meijer et al., 2009 ).
There is limited evidence supporting the use of pharmacological and psychological interventions for depression in the context of schizophrenia (Whitehead et al. 2002; Wykes et al., 2008) . Although effective at treating positive symptoms, Cognitive Behavioural Therapy for psychosis (CBTp) is less effective for treating emotional dysfunction associated with psychosis such as depression, hopelessness and suicide risk (Birchwood, 2003; Wykes et al., 2008; Tarrier et al., 2006) . Whereas traditional CBTp tends to emphasize the importance of changing the content of these appraisals, increasing research attention is being directed toward the benefits of applying acceptance-based approaches to the psychological treatment of psychosis (Tai & Turkington, 2009) . Acceptance-based approaches place less emphasis on altering the content of cognitions in favour of focusing on how individuals relate to these cognitions. One possibility that warrants research attention is whether these newer approaches provide alternative options for conceptualising and treating depression in the context of psychosis.
Acceptance and Commitment Therapy (ACT) conceptualises psychological suffering as being largely caused by experiential avoidance, cognitive entanglement, and associated psychological rigidity that impedes people's ability to take behavioural steps that are consistent with their core values (Hayes & Smith, 2005) . Preliminary findings with nonpsychotic populations provide evidence that ACT can reduce levels of depression (Zettle & Hayes, 1986; Zettle & Raines, 1989; Petersen, 2007) with medium to large effect sizes (Forman et al., 2007; Lappalainen et al., 2007) . In addition, Bohlmeijer et al. (2011) found that an ACT-based early intervention for people with mild to moderate levels of depression (total N = 93) was effective in reducing depressive symptomatology. The ACT intervention led to statistically significant reduction in depressive symptomatology (as assessed by the Center for Epidemiologic Studies Depression Scale; Radloff, 1977) , which were maintained at the three-month post-baseline.
There is growing research interest in the application of ACT to difficulties faced by individuals experiencing psychosis. Randomised controlled trials (RCTs) have shown that individuals receiving ACT demonstrated significantly lower belief in positive symptoms compared to Treatment As Usual (TAU) (Bach & Hayes, 2002; Gaudiano & Herbert, 2006) . Bach and Hayes (2002) also found that the ACT interventions were associated with significantly reduced rates of rehospitalization at follow-up compared to a TAU. In addition, a cross-sectional study of patients with psychotic-spectrum disorders conducted by Shawyer et al. (2007) reported that greater acceptance of voices was associated with lower depression, greater confidence in coping with command hallucinations, and greater subjective quality of life. Recently, we completed a feasibility randomised controlled trial which found that ACT reduced depression in individuals with psychosis to a significantly greater extent than did TAU (White et al., 2011) .
However, these preliminary treatment signals need further scrutiny in order to more precisely specify what additional benefit can be gained from ACT versus standard treatment approaches. Gaudiano (2006) called for greater emphasis to be placed on examining the clinical significance of symptomatic outcome in trials of psychological interventions for psychosis. In line with this call, the authors of the current paper identified participants recruited to the White et al. (2011) RCT who had clinically important levels of depression at baseline assessment. Post-hoc analyses were performed to determine if there were clinically significant changes in depression, anxiety, symptoms of psychosis and psychological flexibility between baseline and three-month post-baseline assessments. Specifically, we were interested to compare whether the proportion of individuals achieving clinically significant changes in depression was greater for those randomised to ACT compared to those randomised to TAU.
Method

Design
A repeated measures design was employed. Participants were assessed at baseline and then again at a point 3-months post-baseline, which was intended to coincide with the end of the delivery of the intervention to those in the ACT arm of the study.
Participants
Participants in the current study were a subsample of participants recruited to a feasibility RCT of ACT for emotional dysfunction following psychosis (ACTp: White et al., 2011);  please consult the White et al. (2011) paper for further details of the inclusions and exclusion criteria. None of the participants in the RCT were acutely unwell with psychosis (as defined by a score ≥ 5 on an item of the PANSS Positive Syndrome subscale). Participants were included in the current study on the basis that they were presenting with clinically important levels of depression at baseline assessment; defined as a score ≥ 8 on the Depression subscale of the Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) . Fourteen of the 27 individuals recruited to the feasibility RCT met this criterion, eight were subsequently randomized to receive ACT and six to TAU; 8 of these individuals were subsequently randomized to receive ACT, whereas 6 were randomised to TAU. Case file reviews were used to ensure that all participants had an ICD-10 (WHO, 1992) diagnosis of a psychotic disorder (i.e., schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic disorder, psychotic disorder NOS), bipolar disorder (with psychotic features), or depressive disorder with psychotic symptoms.
Measures
The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983 ) is a widely used self-report instrument designed as a brief assessment tool of the distinct dimensions of anxiety and depression in non-psychiatric populations. Sellwood et al. (2013) have recently demonstrated that the internal consistency of the anxiety and depression sub-scales of the HADS in a sample of individuals diagnosed with schizophrenia were sufficiently high (α = 0.86 and α = 0.83 respectively).
The Positive Scale of Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) : The PANSS is a 30-item observer rated scale used to assess the presence and severity of positive (e.g. delusions, hallucinatory behaviour) and negative (e.g. blunted affect, emotional withdrawl) symptoms. Psychometric studies have reported good inter-rater reliability and satisfactory internal consistency, construct validity, and concurrent validity in relation to other measures of psychopathology (Kay et al., 1988; . Two research assistants who were blind to the randomisation procedures completed the PANSS (JMcT and LR). According to PANSS accuracy criteria (Kay, 1991; Lambert, 1996) , the two raters achieved highly reliable ratings on PANSS assessments. The AAQ-II has been shown to demonstrate satisfactory structure, reliability and validity (Bond et al., 2011) .
Acceptance and Action
Procedure
The research procedures were approved by the West of Scotland NHS Research Ethics experiences can be part of the problem rather than the solution, (6) Noticing that we can notice: focusing on the context in which mental experiences occur rather on the content of these experiences, and (7) Exploring worry thoughts associated with psychosis. All therapy sessions were recorded and competence and fidelity assessed by an expert in ACT (GM). All participants were also free to receive whatever drug treatments, case management, and/or additional psychotherapy that the clinical team deemed necessary. Research Assistants administering the assessments were blind to treatment allocation.
Analysis
In accordance with previous research (e.g. Jacobson and Truax, 1991) , clinically significant changes on outcome measures were deemed to have been achieved if the following two criteria were met:
1. The change in outcome score was reliable according to the Reliable Change Index (RCI) (RCI < -1.96, or > 1.96).
2. Post-baseline scores fell below clinical cut-off scores.
Jacobson and Truax's (1991) method was used to calculate RCI (see: Figure 1 Jacobson et al. 's method (1984; 1986; 1988 ) (see: Figure 2 ) was used to determine clinically significant cut-off scores for the HADS Anxiety and Depression sub-scales and the AAQ-II for the participants recruited to this study. This technique is based on the rationale that there is a greater likelihood of the participant being in the normative distribution than a clinical distribution after treatment. The cut-off points reflect a point where the probability of coming from each of the distributions is equal. HADS normative data obtained by Crawford et al. Because the PANSS is not routinely used in normative contexts, the authors elected to define clinically cut-off scores for the PANSS on the basis of the median values of the PANSS subscales for the sample of participants included in this study (Positive subscale = 11.5;
Negative subscale = 14.5; General subscale = 30.5).
Fisher's Exact Tests (one-tailed) were used to investigate whether the proportion of participants in the ACT group achieving clinically significant changes in assessment measures was significantly higher than in the TAU group. As an indication of effect size for Fisher's Exact Tests, Odds Ratios were also calculated where possible.
INSERT FIGURE 1 HERE INSERT FIGURE 2 HERE
Results Table 1 provides information relating to the age/sex of the participants and scores on the assessment measures at baseline. There were no significant differences between participants receiving ACT and TAU in age. In terms of ethnicity, all of the participants identified as being 'White British'.
INSERT TABLE 1
The analyses performed to determine if there were clinical significant changes on the outcome measures for the ACT and TAU groups are presented in Tables 2 and 3 respectively.   INSERT TABLE 2 HERE   INSERT TABLE 3 HERE   Table 4 indicates that of the eight individuals who received ACT, six (75%) had clinically significant decreases in depression at 3-month post-baseline. This can be compared with only one of the six individuals (17%) who received TAU. An Odds Ratio indicated that the odds of clinically significant decreases in depression were 15 times more likely in individuals receiving ACT compared to TAU. The difference between the two groups in the proportion of people achieving clinically significant decreases in depression scores was at the threshold of statistical significant (p = 0.05). Table 4 also presents data relating to the comparisons made between the ACT and TAU groups in the proportion of participants achieving clinical significant change on the AAQ-II, HADS-Anxiety subscale, PANSS Positive Syndrome subscale, PANSS Negative Syndrome subscale and the PANSS General subscale. None of the difference between the groups on these measures were statistical significant.
INSERT TABLE 4 HERE Discussion
The current study conducted post-hoc analyses on a subsample of 14 participants presenting with clinically important levels of depression at baseline assessment who had originally been recruited to a randomised controlled trial (RCT) conducted by White et al. (2011) . Unlike the original RCT, the current study investigated clinically significant changes in outcome measures between baseline and 3-months post-baseline in the participants who received ACT (N=8) compared to those receiving TAU (N=6). Compared with participants in the TAU group, participants who received ACT were 15-times more likely to achieve clinically significant decreases in depression (p = 0.05). There were no significant differences between the groups in clinically significant decreases in anxiety, psychological inflexibility, positive symptoms, negative symptoms and general levels of psychopathology (p > 0.05).
Only one previous study has examined clinically significant changes in symptoms associated with an ACT intervention. In a trial of ACT for psychosis, Gaudiano & Herbert (2006) found that 50% of participants in the ACT group reached a clinically significant improvement on Brief Psychiatric Rating Scale total score which was a significantly greater proportion than in the enhanced treatment as usual group (7%). Participants were recruited to the White et al.
(2011) feasibility trial on the basis that they were no longer acutely unwell. Consequently, only a comparatively small number of participants in the current study had clinically significant levels of positive or negative symptoms. As such, it is not surprising that there were no significant differences between the ACT and TAU groups in the number of participants who had clinically significant decreases in positive and negative symptoms from baseline to 3-month post-baseline assessment.
The finding that clinically significant changes in depression can occur in the context of psychosis in the absence of marked changes in positive and negative symptoms is consistent with previous research evidence suggesting that 'post-psychotic' depression emerges independently of positive symptom severity, relapse and negative symptoms Iqbal et al., 2000) . It has been suggested that depression is more closely associated with interpersonal adjustment than severity of psychiatric symptoms (Rocca et al., 2005) .
There were a number of limitations with the current study. The number of participants that were included was small. In addition, the same therapist delivered the ACT intervention across the participants. It may be that the better outcomes noted for the participants receiving the ACT intervention were attributable to the therapist rather than the therapy per se.
Additional research recruiting larger numbers of participants and multiple therapists is required to explore whether the findings reported in this study are replicable. Post-hoc analyses were conducted in this study. Participants were not recruited and into the White et al.
(2011) trial on the basis that they had clinically important levels of depression. Therefore the randomization procedure may not have adequately controlled for potential biases in group allocation.
Conclusions
Depression emerging in the context of psychosis is a common but somewhat neglected issue.
Despite depression being a limiting factor in the long-term prognosis of individuals, there has been an absence of interventions aimed at addressing this issue. The findings from this study tentatively suggest that ACT offers promise for bringing about clinically significant changes in the depression that people with psychosis can experience, however in light of the limitations of the current study further research is required. With this in mind, the authors of the current paper are undertaking a randomised controlled trial of ACT for post-psychotic depression. Table 1 . Information about the age/sex of participants and scores on measures at baseline assessment.
Highlights  Depression can impact negatively on quality of life of individuals with psychosis.  Fourteen participants with depression in the context of psychosis were included.  Eight participants received ACT and six received treatment as usual.  Participants were assessed at baseline and three-months post-baseline.
 Clinically significant changes in depression were more pronounced in the ACT group. Where X 1 = baseline score; X 2 = 3-month post-baseline score; S 1 = the standard deviation at baseline; and r xx = the test-retest reliability Where X 1 , S 1 , X 2 , S 2 specify the means and standard deviations of the participants with psychosis and a normative sample respectively.
